Over 50,000 Anganwadi workers are using it. Now we have live information about 4 million women and children. You just feed in the inputs and you can see the whole information. The analytics are not done every day since there is plenty of datasets. Now we have every aspect of a child’s health and identity. What was its weight last month; what is its weight this month. Who is its mother. What is going on with them. Are they severely malnourished. Do they need the health system to intervene? It is a remarkable system and is now operational on the ground. The ministry is expanding it. Never before has India had a system like this.
Every city under the Indian government’s AMRUT programme needs to have a feacal sludge management plan to receive money under this scheme. These plants will be set up closer to the city so that truckers who carry this waste do not have to travel long distances. It completely eliminates the need to build expensive sewage lines and other infrastructure to transport waste. There is no odour emanating from these plants. In fact our Bengaluru project looks like a garden. This goes a long way in addressing the concerns of residents living in the vicinity as well as local politicians who don’t have to bother that they are living near a sewage plant. The only way you know sewage treatment is going on there is by seeing the trucks coming there. We know urbanization is going to proceed at a rapid pace in India. And for urbanization to proceed in an orderly manner, India would need many pieces of infrastructure. And this is a key piece of infrastructure.
Our trials in a couple of other countries show that if you add a third drug to these two being administered by the government, the disease load falls quite rapidly. The drug in question is Albendazole. This triple drug combination is far superior in reducing microfilaria that causes this disease. Our belief is that If the government approves this programme, this could greatly reduce the chance of a resurgence of the disease. This triple drug therapy wouldn’t have to repeat again and again, unlike the double drug therapy that has to be repeated every six months. This would go a long way in eliminating the disease.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)